(Q45072359)

English

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

scientific article published in October 2004

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

1 reference

based on heuristic

inferred from title

0 references

author name string

Alan N Gordon

1

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Margaret Tonda

2

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Steven Sun

3

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Wayne Rackoff

4

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Doxil Study 30-49 Investigators

5

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

language of work or name

0 references

publication date

1 October 2004

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

95

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

1-8

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.011

7 January 2021

Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.011

7 January 2021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.011

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.011

7 January 2021

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.011

7 January 2021

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.011

7 January 2021

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.011

7 January 2021

Chemotherapy for recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.011

7 January 2021

Identifiers

10.1016/J.YGYNO.2004.07.011

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45072359&oldid=2064552794"